Table 1.

Patient characteristics

	Median (range)
Age	54 years (38–73 years)
# Prior regimens for metastasis	3 (1–15)
Performance status (ECOG)	1 (0–1)
	No. of patients (%), N = 11
Gender: female	11 (100)
Race
White	9 (82)
Black	2 (18)
Receptor status
ER/PR-positive	1 (9)
ER-positive/PR-negative	2 (18)
ER-negative/PR-positive	1 (9)
HER2-positive	0 (0), 1 unknown
ER/PR/HER2-negative	6 (55)
Sites of disease
Liver	4 (36)
Pleura/lung	8 (73)
Lymph nodes	9 (82)
Bone	4 (36)
Skin	2 (18)
Prior treatment (adjuvant/metastatic)
Anthracycline based	11 (100)
Taxane based	11 (100)
Capecitabine based	10 (91)
Gemcitabine	5 (45)
Vinorelbine	4 (36)
CMF	4 (36)
Bevacizumab	1 (9)
Lapatinib	1 (9)
Aromatase Inhibitor	7 (64)
Tamoxifen	2 (18)
Fulvestrant	2 (18)
Oophorectomy	2 (18)
Other hormonal (megace, estradiol)	1 (9)